Combo Immunotherapy in NSCLC: Not These Two Drugs ...Middle East

Pembrolizumab monotherapy remains a standard of care, after trial results show that adding ipilimumab conveys no benefits but incurs greater toxicity. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Combo Immunotherapy in NSCLC: Not These Two Drugs )

Also on site :

• Hamas agrees to release 10 hostages as Trump says there’s a ‘very good chance’ for ceasefire deal this week
• 1 in custody, no shots fired: Police respond to Gaylord Rockies Resort Center Wednesday
• '80s Country Hitmaker Marks 'Well Deserved' Career Milestone 12 Years After Stroke